Use of a new silver barrier dressing, ALLEVYN Ag in exuding chronic wounds.
Recognising and managing wounds at risk of infection is vital in wound management. ALLEVYN Ag dressings have been designed to manage exudate in chronic wounds that are at risk of infection; are displaying signs of local infection; or where a suspected increase in bacterial colonisation is delaying healing. They combine an absorbent silver sulfadiazine containing hydrocellular foam layer, with a perforated wound contact layer and highly breathable top film. The results presented are from a multi-centre clinical evaluation of 126 patients conducted to assess the performance of ALLEVYN Ag (Adhesive, Non Adhesive and Sacrum dressings) in a range of indications. Clinicians rated the dressings as acceptable for use in various wound types in 88% of patients. The majority of clinical signs of infection reduced between the initial and the final assessment. The condition of wound tissue and surrounding skin was observed to improve, and there was significant evidence of a reduction in the level of exudate from initial to final assessment (p < 0.001). Clinicians rated ALLEVYN Ag as satisfying or exceeding expectations in over 90% of patients. The evaluation showed the dressings to offer real benefits to patients and clinicians across multiple indications when used in conjunction with local protocols.
Kotz
Paula
P
E T Consultant Services Inc., Asheville, NC, USA.
Fisher
Jane
J
McCluskey
Pat
P
Hartwell
Samantha D
SD
Dharma
Hussein
H
D000328:Adult; D000368:Aged; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage*; D001458:Bandages; D002908:Chronic Disease; D005122:Exudates and Transudates; D005260:Female; D006801:Humans; D011140:Polyurethanes; D012837:Silver Sulfadiazine / Q000008:administration & dosage*; D016896:Treatment Outcome; D014946:Wound Infection / Q000188:drug therapy*
D000891:Anti-Infective Agents, Local; D011140:Polyurethanes; C081143:allevyn; D012837:Silver Sulfadiazine